These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2316 related items for PubMed ID: 11696734

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [Abstract] [Full Text] [Related]

  • 3. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN, Roemeling S, Kranse R, Schröder FH, van der Kwast TH.
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M, Stamey TA, McNeal JE, Yemoto CM.
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wollan P, Zincke H.
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW.
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM, Koch MO, Eble JN, Lin H, Cheng L.
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [Abstract] [Full Text] [Related]

  • 13. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H.
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [Abstract] [Full Text] [Related]

  • 14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [Abstract] [Full Text] [Related]

  • 15. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
    San Francisco IF, Regan MM, Olumi AF, DeWolf WC.
    J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
    [Abstract] [Full Text] [Related]

  • 16. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H.
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [Abstract] [Full Text] [Related]

  • 17. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H.
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [Abstract] [Full Text] [Related]

  • 18. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
    Li K, Li H, Yang Y, Ian LH, Pun WH, Ho SF.
    Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
    [Abstract] [Full Text] [Related]

  • 19. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC.
    Cancer; 2003 Dec 01; 98(11):2344-50. PubMed ID: 14635068
    [Abstract] [Full Text] [Related]

  • 20. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
    Makarov DV, Sanderson H, Partin AW, Epstein JI.
    J Urol; 2002 Jun 01; 167(6):2440-2. PubMed ID: 11992053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 116.